Introduction
The development of gene therapy for the treatment of cancer is currently an active area of research. Although many of the approaches rely on direct transfer of genes into tumour cells in situ, it is important to minimize inappropriate expression of the therapeutic gene. This can be achieved by directly targeting gene transfer and/ or limiting expression of the therapeutic gene to the target tumour cell.
Many promoters have been used to limit gene expression to specific tumour types, for example, the prostate-specific antigen (PSA) promoter for prostate cancer 1 and the a-fetoprotein (AFP) promoter for hepatocarcinomas. 2 However, a general 'tumour-specific' promoter that could be used to limit gene expression to the tumour cell regardless of the tissue origin has yet to be identified.
Here we have exploited the physiological feature of hypoxia to give optimal gene expression in the tumour cell. Hypoxia is a defining feature of tumours with median oxygen tensions of 1.3-3.9% compared to 3.1-8.7% in normal tissues. 3 Solid tumours, in particular, show relatively aberrant vascularization that causes intermittent/absent perfusion leading to hypoxia. When cells experience hypoxia, a ubiquitous signalling cascade is initiated. 4 This cascade culminates in the formation of a heterodimeric transcription complex, hypoxia inducible factor-1 (HIF-1), that binds to the hypoxia response element (HRE) in the untranslated regions of hypoxically regulated genes. 5, 6 In addition to intratumoural hypoxia, many tumours overexpress HIF-1a as a consequence of the process of oncogenesis. 7, 8 Mutations in several tumour suppressors including von Hippel-Lindau, PTEN and p53 and constitutive activity of AKT have been implicated in promoting HIF-1a accumulation (reviewed in Semenza 9 ). Elevated HIF-1a levels are thought to be an essential part of tumour progression and a marker of highly aggressive disease in several tumour types. [10] [11] [12] Therefore, two tumour-specific routes serve to activate HRE-dependent gene expression, making this a compelling pathway to harness for tumourtargeted gene expression.
We have developed a potent hypoxia responsive promoter (OBHRE) that functions in a range of cell types and gene delivery platforms and gives high levels of transgene expression in hypoxia but has minimal activity in normoxia. [13] [14] [15] In this study, we show that the OBHRE promoter is highly active in the tumour microenvironment but is inactive in normal tissues such as liver, spleen, lung and kidney. The high inducibility combined with low basal activity profile of the OBHRE promoter suggested that this system would be useful for the development of tumour-specific gene therapies. One of the most promising concepts for tumour gene therapy is gene-directed enzyme prodrug therapy (GDEPT) involving the delivery of a gene encoding a prodrugactivating enzyme, which metabolizes a nontoxic prodrug to produce a toxic metabolite. In most cases, this toxic metabolite is freely diffusible and is able to kill neighbouring cells, termed the 'bystander effect'. 16 We have evaluated OBHRE-regulated tumour gene therapy using two GDEPT strategies. Firstly, we used a P450-based GDEPT approach based on the human cytochrome P450 isoform 2B6 (CYP2B6) in combination with the prodrug cyclophosphamide (CPA) to investigate the potency of the OBHRE promoter in a human tumour xenograft model. Secondly, we used the ganciclovir/ thymidine kinase (GCV/TK) strategy to demonstrate that the OBHRE promoter could prevent the toxicity often associated with a systemic GCV/TK GDEPT approach. 17 These data suggest that gene therapy vectors utilizing the OBHRE promoter system would be tumour specific with a high therapeutic potential for the treatment of cancer patients.
Results

Tissue specificity of OBHRE-mediated expression
The activity of the OBHRE promoter was evaluated histologically in B16 murine melanoma tumour xenografts and in the mouse liver, spleen, lung and kidney following administration of the Ad.HRELacZ vector. Activity of the OBHRE promoter was compared to that of the CMV promoter using the Ad.CMVLacZ vector at an equivalent dose. Following intravenous administration of 2 Â 10 9 Ad.CMVLacZ, strong b-galactosidase (bgal) expression was detected 6 days later in the liver (Figure 1a) . Expression was seen to a lesser extent in the spleen, where it was mainly concentrated in the marginal zone sinuses where blood pools around the white pulp ( Figure 1c) . Expression was virtually undetectable in the lung and kidney (data not shown). In contrast, Ad.-HRELacZ-mediated b-gal expression was not detected histologically in the liver, although a few discrete b-gal positive cells were observed in the spleen (Figure 1b and  d) .
B16 tumours treated intratumourally with either the Ad.HRELacZ or Ad.CMVLacZ vector showed expression of b-gal (Figure 1e and f) . The Ad.CMVLacZ vector gave widespread, strong expression throughout the tumour whereas the Ad.HRELacZ vector displayed a more distinct pattern of gene expression. A more detailed histological examination of these B16 tumours was carried out using an antibody to CD31 in combination with an anti-b-gal antibody. CD31 is an endothelial cell marker, and is used in this study as an indicator of perfusion and consequently of tissue oxygenation. These results revealed a distinct zone of non-b-gal expressing cells around the CD31 positive blood vessels in the Ad.HRELacZ-treated tumours where the tissue is likely to be oxygenated (Figure 1h ). Since the b-gal expression was detected distal to the blood vessels, this supports the conclusion that the OBHRE promoter restricts gene expression to the most hypoxic regions that are distal to the blood vessels within this tumour model.
We quantified the level of b-gal expression in these liver and B16 tumour samples using an ELISA (Figure 2 ). The Ad.CMVLacZ vector expressed 1000-fold greater levels of b-gal protein than the Ad.HRELacZ vector in the liver (Figure 2 , black boxes). In the tumour, the Ad.HRELacZ vector expressed high levels of b-gal, similar to the levels detected in the Ad.CMVLacZ-treated tumours. We used real-time PCR analysis to determine the number of adenovirus genomes in each of the B16 tumour and murine liver samples. Virtually equivalent levels of genome were detected in both liver and tumour samples treated with either Ad.CMVLacZ or Ad.HRELacZ ( Figure 2, grey boxes) . These quantitative data, in combination with the histological analysis, illustrate that the OBHRE promoter is strongly active in the hypoxic tumour environment but has a very low basal activity in normal oxygenated organs such as the liver.
Effect of OBHRE-mediated CYP2B6/CPA GDEPT on tumour growth
We used MDA-MB468 breast tumour xenografts to examine the potency of an OBHRE-regulated CYP2B6/ CPA GDEPT strategy (Figure 3 ). Intratumoural delivery of formulation buffer followed by CPA treatment caused no significant effect on tumour growth compared to the formulation buffer alone treated tumours (P¼0.46). In contrast, intratumoural delivery of either the Ad.-HREP450 or Ad.CMVP450 vector at a total dose of 6 Â 10 9 PFU followed by two doses of the prodrug CPA resulted in statistically significant effects on tumour growth when compared with the tumours treated with vector alone (P¼0.0026 and 0.0012, respectively).
These results indicate that the activity of the OBHRE promoter in the Ad.HREP450 vector is strong enough to delay tumour growth in this subcutaneous MDA-MB468 tumour model.
Mitigation of the toxic effects of TK/GCV using the OBHRE promoter
We constructed two vectors, Ad.HRETK and Ad.CMVTK, where expression of the TK gene is regulated by either the CMV or OBHRE promoter. To confirm that the OBHRE promoter could drive hypoxiaregulated expression of TK, MDA-MB468 cells were transduced with either the Ad.HRETK or Ad.CMVTK vector and exposed to hypoxia in vitro. Western blot analysis revealed that TK expression was induced by hypoxia in the Ad.HRETK-transduced cells but was constitutively expressed in both normoxia and hypoxia in the Ad.CMVTK-transduced cells ( Figure 4a) .
Next, the Ad.CMVTK and Ad.HRETK vectors were intravenously administered to mice at a total dose of either 5 Â 10 7 (low dose) or 5 Â 10 8 (high dose) PFU followed by daily GCV-treatment at a dose of 25 mg/kg. The mice were weighed each day to give a general indication of health. In the mice that received the highdose Ad.CMVTK followed by GCV treatment, the body weight decreased significantly (Po0.02, Student's t-test) from day 0 to day 6 ( Figure 4b ). However, there was no significant weight loss in mice treated with Ad.HRETK (P40.80), or 0.9% saline (P40.60) in combination with GCV. In the low-dose Ad.CMVTK (5 Â 10 7 PFU)/GCV treated animals there was also a weight loss from day 0 to day 6, but this was not statistically significant (Po0.2) (data not shown).
In order to measure the extent of tissue damage as a result of Ad.CMVTK/GCV treatment, we analysed serum samples taken from all the mice at the start and end of the study for the level of lactate dehydrogenase (LDH). Elevated LDH is often used clinically as an indicator of liver dysfunction. Elevated levels of LDH were only detected in the mice treated with high-dose Ad.CMVTK in combination with GCV ( Figure 4c ). The Ad.HRETK and control groups did not show any irregularity in the presence of LDH in the serum.
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Since systemically administered adenovirus accumulates mainly in the mouse liver, we examined the livers of the mice used in this study microscopically for evidence of necrosis or inflammation. In the livers retrieved from Figure 1 The OBHRE promoter is active in the hypoxic regions of the tumour microenvironment. The subcutaneous tumours were initiated from the injection of 5 Â 10 6 B16 murine melanoma cells. The mice were injected intratumourally or intravenously with 2 Â 10 9 PFU of either Ad.CMVLacZ or Ad.HRELacZ, where expression of b-gal is driven by either the constitutive CMV or OBHRE promoter, respectively. After 6 days, the livers (a and b), spleens (c and d) and tumours (e and f) were removed and analysed histologically for b-gal expression using X-gal stain. Using a macrophage-specific antibody, we also found extensive macrophage infiltrate in these livers consistent with increased hepatic cellular injury and death. In contrast, the livers taken from the Ad.HRETK and control groups appeared normal. There was no observable effect on the liver morphology with the low-dose Ad.CMVTK vector (data not shown).
We quantified the level of TK expression in the livers from the Ad.CMVTK-and Ad.HRETK-treated mice using real-time RT-PCR. The level of TK mRNA transcribed from the Ad.CMVTK vector was much higher than that mediated by the Ad.HRETK vector, 33-and five-fold for the liver and spleen, respectively (Figure 5b ). Quantification of adenovirus genome content revealed that the amount of Ad.CMVTK or Ad.HRETK genome present in the murine liver and spleen was very similar. These results correlate with the data obtained using the Ad.CMVLacZ and Ad.HRELacZ vectors where a few distinct b-gal positive cells were detected in the spleen. Therefore, the overall basal OBHRE promoter activity appears to be slightly higher in the spleen compared to the liver.
Collectively, these data demonstrate that the hypoxiarestricted gene expression profile of the OBHRE promoter can prevent the toxicity of high-dosages of vectors expressing a potentially liver toxic gene such as TK.
Discussion
In the present study, a hypoxia responsive promoter, OBHRE, was incorporated into an adenoviral vector and There are a limited number of promoters that can maintain their selectivity in an adenovirus vector, 18, 19 and those that do are often weak, emphasizing the potential difficulties of this approach. 20, 21 However, in previous studies, we have shown that the high inducible/low basal activity profile of the OBHRE promoter is maintained in the adenovirus setting in vitro. 13 In this study, we wanted to investigate the activity profile of the OBHRE promoter in vivo. Following intravenous delivery of the Ad.CMVLacZ vector we detected strong b-gal expression, particularly in the liver, which is known to express high levels of the Coxsackie/Adenoviral Receptor (CAR). 22 In contrast, we found that the OBHRE promoter had a very low basal activity in organs such as liver, spleen, lung and kidney such that b-gal expression in the liver was 1000-fold lower than that driven by the CMV promoter. However, the OBHRE promoter mediated strong b-gal expression in the tumour microenvironment, comparable to that driven by the CMV promoter. Since the CMV promoter has been recognized as one of the strongest promoters in an adenoviral context, 23 the induced activity of the OBHRE promoter observed in the tumour approaches the maximum as benchmarked by the CMV promoter. Interestingly, the OBHRE-mediated expression in the tumour model occurred predominantly at sites distal to blood vessels further supporting the physiological regulation within the tumour microenvironment.
In human tumours, increased expression of the HIF-1 transcription factor is not only a result of physiological stimulation but also genetic alterations. Loss of HIF-1 expression in tumour cells is associated with decreased xenograft growth and decreased angiogenesis. 24, 25 The ability to adapt to adverse physiological conditions is an essential part of tumour progression. It is believed that elevated HIF-1 levels plays a pivotal role in oncogenesis in promoting angiogenesis and metabolic adaptations in common solid tumours.
8,24-26, For example, overexpression of HIF-1 is considered to be a strong marker in earlystage cervical cancer. 27 In this study, we show that the activity of the OBHRE promoter drives sufficient expression of CYP2B6 in a tumour xenograft model to delay tumour growth in the presence of the prodrug CPA. As predicted from previous studies using this GDEPT strategy, the delay in the growth of tumours receiving Ad.HREP450 or Ad.CMVP450 began just over a week following the administration of CPA. 28 The GDEPT strategy described in this study included two administrations of the CPA prodrug on days immediately following vector delivery. Perhaps the tumour growth delay could be further improved by repeating the CPA administrations at later time points such as day 25 (reviewed in Waxman et al. 29 ). In addition, the elevated HIF-1 activity in many clinical human tumour types would be extremely beneficial to further enhance the efficacy and safety profile of an OBHRE-targeted tumour therapy.
Hepatic sequestration of vector is one of the major limitations for using adenovirus vectors in the context of 'suicide' gene therapy. As indicated in this study, the majority of systemically administered adenovirus will accumulate, and be expressed in, the liver. Several studies report severe hepatic dysfunction following adenovirus-mediated TK gene transfer and GCV administration, illustrating that the generally accepted theory that GCV only kills proliferating cells does not hold true. 17, 20, 30 Several tissue-specific promoters have been investigated for their ability to mitigate the liver toxicity associated with TK-mediated 'suicide' gene therapy. 31, 32 In the present study, we reasoned that the OBHRE promoter would be suitable for this purpose due to its low basal activity in normal tissue. We compared the in vivo toxicity of the Ad.HRETK and Ad.CMVTK vectors. Ad.CMVTK/GCV treatment caused remarkable toxicity, including weight loss, elevated serum LDH levels and severe liver necrosis and inflammation. In contrast, Ad.HRETK/GCV caused no liver or serum abnormalities. These results indicate that the basal activity profile of the OBHRE promoter in normal organs such as the liver can prevent the toxicity of high doses of vector expressing a potentially toxic gene such as TK.
Combining transcriptional with transductional targeting could further enhance the specificity of particular 8 PFU) Ad.HRETK or Ad.CMVTK followed by GCV (25 mg/kg) administration on (b) mouse body weight (grey bars are weights at day 0 and black bars are weights at day 6) and (c) serum levels of lactate dehydrogenase (grey bars are NaCl-treated mice and black bars are GCV-treated mice). Data are plotted as a mean7SEM, n¼5. *Two LDH values in the high-dose Ad.CMVTK-treated mice were above the detection limit of this assay (420 000 U/ml) and therefore data for n¼3 rather than n¼5 are shown for this group.
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K Binley et al gene therapy vectors. 33 Transductional targeting alters the natural infection pathway; in the adenovirus this is typically achieved by modifying the knob domain of the adenovirus fibre, which normally binds to CAR. 34 Transductional targeting could be combined with OBHRE transcriptional targeting for the development of novel tumour-targeted gene delivery systems.
Genetically modified adenoviruses that selectively replicate in tumour cells show great promise for the treatment of tumours. 35 Several different tissue-specific promoters have been used to direct the expression of genes essential for viral replication, leading to the generation of conditionally replicating adenoviruses (CRADs) targeted to tumour cells. [36] [37] [38] The low basal activity combined with the high tumour activity of the OBHRE promoter suggests that it would be ideally suited for use in the context of a CRAD.
Other studies using tumours established from stable cell lines expressing a hypoxia-regulated prodrug activating enzyme show a delay in tumour growth in the presence of the prodrug. 39, 40 In this study, we have characterized the efficacy of the hypoxia responsive promoter using direct administration of the gene therapy vector into established tumour models. We have shown that the OBHRE promoter gives strong expression in the tumour microenvironment while limiting undesired transgene expression in normal tissue. In addition, we have shown that the OBHRE promoter gives therapeutically relevant expression levels in a tumour model while mitigating liver toxicity by preventing expression of a potentially toxic gene. Therefore, we believe that the OBHRE promoter could be important for the development of tumour gene therapy strategies with an improved safety profile and therapeutic index. 
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Materials and methods
Cells and reagents
The human breast cancer cells MDA-MB468 and B16 murine melanoma cells (ECACC, Wiltshire, UK) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal calf serum, 2 mM L-glutamine and 2 mM nonessential amino acids (Sigma-Aldrich, Dorset, UK). The PER.C6 adenovirus helper cell line (Crucell, Holland) was maintained in DMEM supplemented with 10% fetal bovine serum (nondecomplemented) and 10 mM MgCl 2 (Invitrogen, The Netherlands). For suspension culture, the PER.C6 cells were grown in Ex-Cell 525 medium (JRH Biosciences). Transfections were carried out using lipofectamine (Invitrogen, The Netherlands) according to the manufacturer's instructions. For hypoxic exposure, cells were exposed to 0.1% O 2 in a 5% CO 2 humidified incubator (Heto, Camberley, UK) for 16 h at 371C.
Construction of recombinant adenovirus vectors
The construction of the first-generation recombinant Ad.CMVLacZ, Ad.HRELacZ, Ad.CMVP450, Ad.-HREP450 and Ad.CMVGFP adenoviruses has been described previously. 13, 15 The construction of the recombinant Ad.CMVTK and Ad.HRETK is described below. The TK gene was donated in the plasmid pRVTK (a gift from E Kotsopoulou). The TK gene was removed as an EcoRI fragment and cloned into pcDNA3.1Zeo+ to create pZTK (Invitrogen, The Netherlands). In order to generate the Ad.CMVTK and Ad.HRETK adenovirus vectors, the TK cDNA was removed from pcDNA3.1Zeo+ as a HindIII-XbaI fragment and cloned into the pGL3-OBHRE plasmid to replace the luciferase gene.
14 This plasmid is called pHRETK. The pAd.HRETK transfer vector was then created by a three-way ligation of the 333 bp NheISalI fragment and the 1512 bp SalI-BamHI fragment from pHRETK into the XbaI-BglII sites of the AdTrack plasmid. 41 The pAd.CMVTK transfer vector was created by cloning the KpnI-XhoI TK fragment from pZTK into the KpnI-XhoI sites of the AdTrackCMV plasmid. 41 The AdTrackCMV transfer plasmid contains a CMVGFP expression cassette. Recombination of the transfer vectors with the Ad5 genome plasmid AdEasy-1 was carried out in bacterial cells according to the manufacturers' protocol (Quantum Appligene, France). The resulting full-length recombinant adenovirus genome plasmids were linearized using PacI prior to transfection into the adenovirus helper cell line PER.C6. Adenovirus stocks were purified using standard CsCl gradients. Viral titre was determined by standard particle determination (the extinction coefficient is 1.1 Â 10 12 virus per OD 260 unit) and limiting dilution assays.
In vivo studies
All experiments were performed with 4 to 5 week-old female Nude (nu/nu) mice. For the b-galactosidase biodistribution experiment, subcutaneous tumours were established in the left flank by injection of 5 Â 10 6 B16 murine melanoma cancer cells. Once tumours had grown to 200 mm 3 , mice were anaesthetized with isofluran forene (Minerve, Bondoufle, France). Tumours were directly injected with 50 ml of test substance, 2 Â 10 9 PFU of either Ad.CMVLacZ or Ad.HRELacZ. For the determination of b-gal expression in the liver, Nude mice were anaesthetized before receiving a 50 ml tail vein injection of 2 Â 10 9 PFU of either Ad.CMVLacZ or Ad.HRELacZ. All mice were killed 3 days posttreatment and tissues harvested for analysis.
For the CYP2B6/CPA efficacy study, MDA-MB468 (human breast carcinoma) cells were implanted at 5 Â 10 6 cells/100 ml DMEM made up with 30% Matrigel (Stratech, UK). Tumour cells were implanted in the right and left flank and allowed to develop to a mean diameter of 5 mm prior to the start of the protocol. Three 50 ml intratumoural doses of 5 Â 10 8 PFU of either Ad.CMVP450, Ad.HREP450 or Ad.CMVGFP were injected on days 0, 2 and 4. The mice were randomized, and on days 5 and 6 the animals received either a 200 ml intraperitoneal injection of CPA at a dose of 150 mg/kg or formulation buffer (phosphate-buffered saline). Gross effects of CPA on tumour growth were studied using caliper measurements. Tumour measurements for each tumour (two tumours per mouse) were taken daily. Mean tumour volumes of individual tumours were calculated using the formula p/6(
3/2 where d is diameter. The total tumour growth (area under the curve, AUC) in CPA-treated and control mice was compared using the nonparametric one-way Mann-Whitney test.
For the TK/GCV toxicity study, 100 ml containing either formulation buffer (control) or a total viral dose of 5 Â 10 7 or 5 Â 10 8 PFU of either Ad.HRETK or Ad.CMVTK was delivered by a tail vein injection. The mice were then divided randomly into two groups of five animals and they received twice daily intraperitoneal injections (days 1-5) of either GCV (25 mg/kg) or 0.9% NaCl. The health of the animals was monitored throughout the experiment and weight measurements were recorded daily. Organs were harvested on day 6.
Real-time PCR analysis
Primer Express (PE Applied Biosystems, Foster City, CA, USA) was used to design primer and probe sequences to amplify murine GAPDH, TK, adenovirus serotype 5 genome and b-actin (described in Table 1 ). All probes were synthesized with 5 0 FAM reporter dyes except for the TK probe, which was labelled with a 5 0 VIC reporter. All probes were 3 0 labelled with TAMRA dye quencher. DNA was isolated from tissues using the DNeasy tissue kit (QIAGEN, West Sussex, UK). DNA was extracted from the adenovirus standard (Ad.CMVLacZ, 1 Â 10 11 genomes/ml) using the QIAamp DNA blood mini kit (QIAGEN, West Sussex, UK). RNA was isolated from tissue harvested into RNAlater (Ambion, Austin, TX, USA). Total RNA was extracted using the RNeasy tissue kit (QIAGEN, West Sussex, UK). Contaminating DNA in the total RNA samples was removed using the DNA-free kit (Ambion, Austin, TX, USA). A total of 50 ng of DNA and 12.5 ng of RNA was analysed in each real-time PCR reaction. Cell number was estimated from the DNA concentration based on the assumption that there is 6.6 pg DNA/cell.
All reactions were performed using the ABI Prism 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). The C T values, the cycle at which the formation of specific product is detected, were recorded. Using these C T values, relative levels of TK mRNA and Ad5 genome were normalized using the GAPDH or b-actin as an internal reference, respectively. An adenovirus genome standard of known titre was amplified alongside samples and used to calculate genome copy number.
Tissue protein analysis
Protein samples were quantified using the Detergent Compatible (DC) Protein Assay Kit (BioRad, York, UK) together with a Dynex Technologies MRX plate reader using a bovine serum albumin protein standard.
For the detection of TK protein in cell extracts, 30 mg of each sample was Western blotted and probed with a custom-made TK primary antibody (Abcam, Cambridge, UK) at 1:600. The secondary goat anti-chicken HRPconjugated antibody was used at 1:10,000 (Abcam, Cambridge, UK).
For analysis of b-gal expression, tissue sections were lysed in 500 ml of lysis buffer (b-gal ELISA kit, Roche, Lewes, UK) including complete mini protease inhibitor cocktail (Roche, Lewes, UK). The tissue was freeze/ thawed and centrifuged at 13 000 rpm for 10 min and the supernatants were assayed using the b-gal ELISA kit according to the manufacturer's instructions. Lysates were diluted as appropriate to ensure that all readings were measured within the linear range of the assay. The b-gal activity was normalized to total protein levels.
Lactate dehydrogenase measurements
Blood was collected in heparinized tubes for lactate dehydrogenase (LDH) activity analysis. LDH activity was evaluated with the automated VITROS 
Histological analyses
For immunological analysis, tissue sections were fixed in acetone and endogenous peroxidase activity was blocked with 0.2% H 2 O 2 in methanol. Slides were incubated in 5% goat serum in order to block nonspecific protein binding followed by incubation with the appropriate primary antibody. For the double-staining procedure, the biotinylated rat anti-CD31 antibody (BD Biosciences, Oxford, UK) was used at a dilution of 1/100 and detection was carried out using the alkaline phosphatase labelled streptavidin (Vector Laboratories, Peterborough, UK) at a dilution of 1/300. Staining was visualized using the NBT/BCIP chromogen containing levamisole (Roche, Germany). Slides were blocked again using 10% NGS followed by the addition of rabbit anti-b-gal antibody at a dilution of 1/300. Slides were washed thoroughly and detection was performed using the Vector rabbit ABC kit secondary reagent and lacZ labelled streptavidin (Vector Laboratories, Peterborough, UK) at a dilution of 1/500. Macrophages were detected using the mouse anti-HAM-56 primary antibody (Dako, Glostrup, Denmark) at a dilution of 1/50. Biotinylated goat anti-mouse IgM (Sigma-Aldrich, Dorset, UK) was used at a dilution of 1/100 followed by incubation with the tertiary reagents from the Vector stain ABC kit. Staining was visualized using DAB (Vector Laboratories, Peterborough, UK). Sections were counterstained for 5 min using Harris's haematoxylin.
X-gal staining for b-gal was visualized by incubating sections in X-gal solution (1 mM X-gal, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM MgCl 2 in PBS) at 371C for 2 h. Sections were counterstained in 1% alcoholic eosin, dehydrated through graded alcohols, cleared in xylene and mounted in DPX.
